

8. AML Academy 2025

Study Alliance Leukemia – AML Cooperative Group – CELL



SAL
Studienallianz
Leukämie

AMLCG
AML
Cooperative Group



13th/14th November 2025

PRELIMINARY AGENDA

Thursday, 13th November 2025

AML Academy I

13:00–13:05	Welcome	
13:05–13:20	Acute Leukemias in Germany: New Epidemiological Benchmarks	Claudia Baldus
13:20–13:35	Efficacy and tolerability of HAM-Venetoclax in the real world	Andrew Berdel
13:35–13:50	HMA-Ven in SAL-AMLCG-CELL registries: outcomes and prognostic implications	Lydia Kretschmer
13:50–14:05	HMA-Ven in CBF-AML	Leo Ruhnke
14:15–15:15	Interactive case discussions for the SAL-AMLCG AML Board	Björn Steffen/ Sebastian Wolf Julia Unglaub/ Tim Sauer Martina Crysandt
15:30–15:50	When we're spoilt for choice in donor selection: How to pick the best one?	Johannes Schetelig
15:50–16:10	Clonal hematopoiesis in AML long-term survivors	Klaus Metzeler
16:10–16:30	TP53 mutated CHIP to AML: new insights?	Lynn Quek

AML Academy II

16:45–17:15	How I treat APL in 2025	Maria Teresa Voso
17:15–17:45	Graveyard of new drugs or land of hope? Treatment of relapsed-refractory AML	Emma Searle
17:45–18:15	What's my standard induction in 2025?	Naval Daver
18:15–18:20	Closing remarks	

From 19:00 Networking Dinner

Friday, 14th November 2025

SAL-AMLCG Steering Committee Meeting

08:00–10:00 Steering Committee Meeting

Joint Study Group Meeting of SAL, AMLCG

10:30–13:00 Updates on current, past and future
projects and trials

Lunch Break

14:00–16:00 Updates on current, past and future
projects and trials

Location

Scandic Frankfurt Museumsufer
Wilhelm-Leuschner-Straße 44
60329 Frankfurt am Main

and online
via Zoom

Registration
www.aml-academy.de



Organizer



GWT-TUD GmbH
Freiberger Str. 33
01067 Dresden

Juliana Binder


Mobil: 0151 2333 7972
juliana.binder@g-wt.de

Main Sponsor



Jazz Pharmaceuticals

Sponsors



AbbVie Deutschland GmbH & Co. KG (20.000,00 €), Astellas Pharma GmbH (10.000,00 €), BeOne Medicines Germany GmbH (5.000,00 €), Bristol-Myers Squibb GmbH & Co. KGaA (5.000,00 €), Johnson & Johnson (10.000,00 €), Jazz Pharmaceuticals (30.000,00 €), Neovii Biotech GmbH (5.000,00 €), Novartis (5.000,00 €), Pfizer (10.000,00 €), Servier (5.000,00 €), Otsuka Pharma GmbH (10.000,00 €), Daiichi Sankyo Deutschland GmbH (10.000,00 €)